Show your stripes

On Rare disease day | February 28th

Join us in bringing awareness and support to the more than 25 million Americans living with a rare disease.

Get involved


Long-term overall survival data from participants in the CENTAUR ALS trial have been published in Muscle & Nerve. 



The CENTAUR ALS trial data have been published in the New England Journal of Medicine.

Learn More


An unconventional approach redefines what’s possible.

To go far, we must go together. By collaborating with patients, families, physicians and partners, we’re working towards our destination by developing a drug that prevents nerve cell degeneration. Driven by innovation and relentless curiosity, our connections propel us forward in pursuit of what’s next.

Our Company

In Pursuit of
Every Moment.

Together, with our growing leadership team of industry veterans, physicians and scientists, we seek new perspectives from research, from each other, and most importantly, from patients and their families. We know the answer is out there. And every day brings us closer to reaching it.

View the Pipeline


We believe in the power of the individual, the strength of personal connection, and the passion of humanity to address the effects caused by neurodegenerative diseases. Amylyx was built on the foundation of audacious curiosity, relentless drive, and meaningful relationships. If that sounds like you, we’d love to talk.

View Open Positions

Clinical Trials

Pegasus Alzheimer’s Trial

PEGASUS is a 3:2 randomized, double-blind, multi-center, placebo-controlled trial evaluating the safety, tolerability and activity of AMX0035 in patients with late mild cognitive impairment or early dementia due to Alzheimer’s disease over 24 weeks.

More About Pegasus

Centaur ALS Trial

The CENTAUR trial of AMX0035 was a 24-week, randomized, double-blind, placebo-controlled Phase II clinical trial completed in late 2019, which demonstrated statistically significant treatment benefits for people with ALS.

More About Centaur